Guide – Immuno-oncology clinical trials: Considerations in managing speciality & central laboratory services for success

Navigate biomarker complexity, optimize trial design, and accelerate timelines with expert lab support.

Immuno-oncology trials are among the most complex in clinical research requiring a deep understanding of immune response, precise patient selection, and advanced biomarker testing.

This guide from Cerba Research, a global specialty and central laboratory, outlines the key considerations for sponsors and clinical teams looking to successfully execute I/O trials.

Inside the guide, you’ll learn:

• The three nonnegotiable lab capabilities for I/O trials:
  Flow Cytometry (FCM), Immunohistochemistry (IHC), and Next-Generation Sequencing (NGS)
• How to apply biomarker strategies for patient stratification, response prediction, and regulatory readiness
• What to consider when selecting a lab partner, including global harmonization, assay validation, and real-time data access
• How Cerba Research supports early and late-phase trials across solid tumors and hematologic malignancies

Whether you’re launching a first-in-human study or scaling to Phase III, this guide will help you de-risk your development strategy and enhance trial outcomes.